Newbery Gisella, Lima Neiberg de Alcantara, Gurgel Livia Andrade, Driscoll Ross, Lima Carol C V
Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
J Cardiol Cases. 2019 Jun 7;20(3):88-91. doi: 10.1016/j.jccase.2019.05.001. eCollection 2019 Sep.
Advances in chemotherapy and radiotherapy have greatly improved cancer survival, but their side effects can sometimes be more dangerous than the cancer itself. Understanding these risks is especially important when the consequences are as life-threatening as heart failure. Melphalan and fludarabine are drugs used in many chemotherapy regimens and are not usually associated with cardiotoxicity. In this report we present a patient that developed acute heart failure followed by persistent heart failure after conditioning with these drugs following a bone marrow transplant. < The chemotherapeutic agents melphalan and fludarabine used individually are rarely associated with cardiotoxicity. However, this case report of myocarditis and persistent heart failure, adds to the growing literature suggesting an exponential rise in cardiac complications when these agents are used in combination. Awareness of this association is important to consider when choosing and monitoring a chemotherapy regimen.>.
化疗和放疗技术的进步极大地提高了癌症患者的生存率，但它们的副作用有时可能比癌症本身更危险。当后果像心力衰竭一样危及生命时，了解这些风险尤为重要。美法仑和氟达拉滨是许多化疗方案中使用的药物，通常与心脏毒性无关。在本报告中，我们介绍了一名患者，该患者在骨髓移植后使用这些药物进行预处理后出现急性心力衰竭，随后发展为持续性心力衰竭。<单独使用的化疗药物美法仑和氟达拉滨很少与心脏毒性相关。然而，这例心肌炎和持续性心力衰竭的病例报告进一步增加了越来越多的文献报道，表明这些药物联合使用时心脏并发症呈指数级上升。在选择和监测化疗方案时，认识到这种关联很重要。>
